UK In Major Move To Boost Commercial Clinical Trials & Improve Life Sciences Environment
The publication of two major reports has led the UK government to announce a £650m “Life Sci for Growth” package to bolster the life sciences sector.
You may also be interested in...
Legal Challenge Could Put UK Drug Pricing Deal At Risk
The body representing generics and biosimilars companies in the UK is seeking a seat at the table as negotiations on a new voluntary price scheme get under way.
EU Adopts New Rules On UK-Wide Approvals For Novel Drugs
Having been passed by the European Parliament and now the Council of the EU, new legislation will clear up some of the issues raised by Brexit relating to trade in medicines between Great Britain and Northern Ireland.
UK Reveals Seven Partners Whose New Drug Approvals It Will Recognize
The UK regulator, the MHRA, says that while it will recognize drug approvals granted in the EU and a selection of other countries, it will remain a “sovereign regulator” with the ability to reject applications if they don’t meet its standards.